Ramon Mohanlal

Directeur/Membre du Conseil chez

Seed Therapeutics, Inc.

67 ans

51 relations

Health Technology

Consumer Services

Commercial Services

Profil

Ramon W.
Mohanlal is currently a Director at Seed Therapeutics, Inc. Prior to his current position, he served as Director, Chief Medical Officer, and Executive VP-R&D at BeyondSpring, Inc. from 2015 to 2023.
Ramon also held positions as Chief Medical Officer at Vertex Pharmaceuticals, Inc., Clinical Head-Established Oncology Products at Novartis AG, and Chief Executive & Medical Officer at BioPremiere, Inc. He was also a Principal at Glaxo Wellcome Plc and Pharmacia Corp.
Ramon holds a doctorate from the University of Leiden and an MBA from American InterContinental University System, Inc.

Postes actifs de Ramon Mohanlal

Sociétés	Poste	Début
Seed Therapeutics, Inc. Seed Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Seed Therapeutics, Inc. is a biotechnology company pioneering the development of first-in-class molecular glue degraders to target disease-causing proteins traditionally considered undruggable. The company is based in King of Prussia, PA. Utilizing their proprietary RITE3™ platform, Seed Therapeutics accesses the full spectrum of over 600 human E3 ligases to design precise targeted protein degradation therapies. The company's lead candidate, ST-01156, an orally administered, brain-penetrant RBM39 degrader, is in phase 1 clinical trials for cancers including Ewing sarcoma and hepatocellular carcinoma, demonstrating potent tumor regression in preclinical models. Beyond oncology, the company advances programs in neurodegeneration, such as oral tau degraders targeting pathological protein aggregation in Alzheimer’s disease. Seed Therapeutics integrates structural biology, molecular modeling, and proteomics to create treatments addressing unmet medical needs with high specificity and minimal off-target effects. The company collaborates with industry leaders and emphasizes rigorous clinical translation to transform scientific insights into precision medicines for cancer, neurological disorders, and immunology. The company was founded by Avram Hershko, Lan Huang, Michele Pagano, Ning Zheng. The CEO is Lan Huang.	Directeur/Membre du Conseil	01/08/2020

Tous les postes actifs de Ramon Mohanlal

Anciens postes connus de Ramon Mohanlal

Sociétés	Poste	Fin
BEYONDSPRING INC.	Directeur Technique/Scientifique/R&D	16/02/2023
NOVARTIS AG	Corporate Officer/Principal	01/07/2015
BioPremiere, Inc. BioPremiere, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company	Directeur Général	01/01/2009
INTERLEUKIN GENETICS, INC	Directeur Technique/Scientifique/R&D	17/08/2007
Glaxo Wellcome Plc Glaxo Wellcome Plc Pharmaceuticals: MajorHealth Technology Researches, develops, manufactures and markets pharmaceuticals	Corporate Officer/Principal	-

Voir l'expérience en détail de Ramon Mohanlal

Formation de Ramon Mohanlal

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Ramon Mohanlal

Relations

Relations au 1er degré

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Entreprise privées	10
Vertex Pharmaceuticals, Inc. Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis	Health Technology
Glaxo Wellcome Plc Glaxo Wellcome Plc Pharmaceuticals: MajorHealth Technology Researches, develops, manufactures and markets pharmaceuticals	Health Technology
Interleukin Genetics, Inc. Interleukin Genetics, Inc. Pharmaceuticals: MajorHealth Technology Develops personalized health products	Health Technology
American InterContinental University System, Inc. American InterContinental University System, Inc. Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Novartis AG Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products	Health Technology
Pharmacia Corp. Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Researches, manufactures and sells pharmaceuticals	Health Technology
University of Leiden University of Leiden Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
BioPremiere, Inc. BioPremiere, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company	Health Technology
BeyondSpring, Inc. BeyondSpring, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures cancer therapies	Health Technology
Seed Therapeutics, Inc. Seed Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Seed Therapeutics, Inc. is a biotechnology company pioneering the development of first-in-class molecular glue degraders to target disease-causing proteins traditionally considered undruggable. The company is based in King of Prussia, PA. Utilizing their proprietary RITE3™ platform, Seed Therapeutics accesses the full spectrum of over 600 human E3 ligases to design precise targeted protein degradation therapies. The company's lead candidate, ST-01156, an orally administered, brain-penetrant RBM39 degrader, is in phase 1 clinical trials for cancers including Ewing sarcoma and hepatocellular carcinoma, demonstrating potent tumor regression in preclinical models. Beyond oncology, the company advances programs in neurodegeneration, such as oral tau degraders targeting pathological protein aggregation in Alzheimer’s disease. Seed Therapeutics integrates structural biology, molecular modeling, and proteomics to create treatments addressing unmet medical needs with high specificity and minimal off-target effects. The company collaborates with industry leaders and emphasizes rigorous clinical translation to transform scientific insights into precision medicines for cancer, neurological disorders, and immunology. The company was founded by Avram Hershko, Lan Huang, Michele Pagano, Ning Zheng. The CEO is Lan Huang.	Commercial Services